PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor.

Date publication

février 2026

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr LINDNER Véronique , Dr MASSFELDER Thierry , Dr IDOUX-GILLET Ysia

Tous les auteurs :
Mallah H, Soultani S, Diabasana Z, Lindner V, Barthélémy P, Idoux-Gillet Y, Massfelder T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41749814

Résumé

PC is the second most common malignancy in men, and progression to metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) remains incurable. Current treatments for mCRPC include chemotherapy, immunotherapy, radiopharmaceuticals, and second-line androgen receptor signaling inhibitors (ARSIs) such as Abiraterone. PARP inhibitors (PARPis) have recently shown clinical benefits in tumors with homologous recombination repair (HRR) deficiencies, particularly BRCA1/2 mutations. Combining PARPi with ARSIs has improved progression-free (PFS) and overall survival (OS), especially in ARSI-naïve patients, but limited data exist for resistant disease.

Mots clés

BRCA/HRR deficiency, PARP inhibitors, abiraterone resistance, combination therapy, mCRPC, prostate cancer

Référence

Cancers (Basel). 2026 02 9;18(4):